Information Center

  • Move News
  • Move FAQ
  • Move Queries&Feedback

News News

Total 48

News Search
  • Samyang Biopharm 2019.08.05
    Samyang Biopharm USA Inc. Hires Global Anticancer Drug Experts and Begins Its Operations In Earnest
    Samyang Biopharm USA Inc. Hires Global Anticancer Drug Experts and Begins Its Operations In Earnest

      ▲ President Hyun-Jung Lee (Helen Lee) of Samyang Biopharm USA and the two global anticancer drug experts who joined Samyang Biopharm USA. From left to right: President Hyun-Jung Lee (Helen Lee), Vice President Sean D. McKenna, and Vice President Jeffrey Lange. Samyang Biopharm USA, a global biotech subsidiary of the Samyang Group, is set to begin its operations in earnest.    Samyang Biopharm announced on Aug. 5 that Samyang Biopharm USA, which was established in 2018, hired two global anticancer drug experts as executives and has started its operations in full swing.    Samyang Biopharm USA is an overseas subsidiary established by Samyang Biopharm in August 2018 in Kendall Square of Boston, USA—the hub of biotechnology industry—with the goal of developing innovative anticancer drugs and orphan drugs.    Fully taking advantage of its location, Samyang Biopharm USA is planning to increase the biopharmaceutical development speed and success rates by implementing the open innovation strategy that discovers, introduces, and develops biopharmaceutical technologies and compounds at an early time and by conducting global clinical trials on anticancer drug leads, which are researched by its head office in Korea. Located at the core of Boston’s Biotech Valley, Kendall Square is an area optimized for global open innovation that is equipped with the academic, industrial and research ecosystem, which consists of Novartis, Pfizer, Biogen, etc. centering around the Massachusetts Institute of Technology (MIT).    The executives who joined Samyang Biopharm USA are Dr. Sean D. McKenna, an expert in cancer immunotherapy drug R&D, and Jeffrey Lange, former Vice President of Baxalta, who is an expert in biotech business development.    Dr. McKenna is an authoritative figure in the fields of antibody technologies, protein engineering, immunology and oncology. He has led many development and commercialization projects for anticancer drugs that are currently used in clinical practice, including the anticancer immunotherapy drug Bavencio (Avelumab) from Merck, a global biotech firm with its headquarters in Germany. Anticancer immunotherapy drugs are referred to as the third generation drugs as the drugs activate the patient’s immune system and help immunocytes to attack cancer cells unlike the first or second anticancer drugs that target the cancer itself.   Vice President Lange is a business development expert who has successfully led multiple joint development projects and licensing contracts based on the accurate valuation of anticancer drugs. While working at Baxalta (currently Shire), which specializes in developing orphan drugs, he took the lead for two anticancer immunotherapy drug development contracts, each worth USD 1.6 billion: joint anticancer immunotherapy drug development with Symphogen and joint CAR-T cell therapy drug development with Precision BioSciences.    President Hyun-Jung Lee (Helen Lee), who now leads Samyang Biopharm USA, is also a specialist (MD, MHCM) and expert in clinical development of anticancer drugs. Before joining Samyang Biopharm, she led the way to obtain US approval for Erbitux (Cetuximab) as the first-line treatment of head and neck cancer in Eli Lilly’s headquarters and Baxalta (currently Shire), and led the European approval and global clinical trials for Onivyde (nanoliposomal irinotecan) as the second-line treatment of pancreatic cancer. President Lee has worked as Chief Strategy Officer (CSO) and Chief Medical Officer (CMO) at Samyang Biopharm since 2016 before she started serving as President of Samyang Biopharm USA from 2018.    President Lee said,“With Samyang Group’s long-term commitment to biopharmaceuticals, we have set up a subsidiary in Kendall Square and are additionally hiring global experts in clinical and licensing areas. Putting together the promptness of Kendall Square and endurance of the Samyang Group, we will unveil innovative anticancer immunotherapy drugs and orphan drugs.”    Meanwhile, Samyang Biopharm USA has established the Scientific Advisory Board (SAB) with the best experts in anticancer treatment for advice in the latest anticancer technologies and future product portfolios. Currently, members of the Samyang Biopharm SAB (Scientific Advisory Board) include Professor Yung-Jue Bang of the Division of Hematology/Oncology at Seoul National University Hospital; Director Louis M. Weiner of Lombardi Comprehensive Cancer Center at Georgetown University, USA; and Dr. Scott J. Antonia at Duke Cancer Institute’s Center for Cancer Immunotherapy, USA. 

  • Samyang Biopharm 2019.08.01
    Samyang Biopharmaceuticals Corporation Launches Advertisements for Transdermal Arthritis Patch Rheumastop®
    Samyang Biopharmaceuticals Corporation Launches Advertisements for Transdermal Arthritis Patch Rheumastop®

      Samyang Biopharmaceuticals Corporation, Samyang Group’s biopharmaceutical affiliate, unveils advertisements for the transdermal arthritis patch Rheumastop® to the public for the first time since its launch. To raise brand awareness for the transdermal arthritis patch Rheumastop® and deliver the message that it can stop pain once it is applied to the skin, Samyang Biopharmaceuticals Corporation announced on August 1 that it is launching radio and video advertisements from August 1 with the slogan” Stopped once applied! Pain stops! Rheumastop!’ which uses the word “stop” from its name.   Rheumastop® is a transdermal arthritis patch developed by Samyang Biopharmaceuticals Corporation. When a patch is applied to the area of pain per day, the anti-inflammatory analgesic drug diclofenac is absorbed topically through the skin only to the affected area and relieves inflammation and pain. Since it only works on the affected area, it is free from any side effects such as gastrointestinal disorders, which might occur when the same drug is taken orally.   These advertisements were designed to inform consumers of the brand name Rheumastop® and make more people buy it based on its name in pharmacies. Following its shift towards directly selling Nicostop® and Rheumastop®, Samyang Biopharmaceuticals Corporation is strengthening its transdermal patch line by unveiling the family brand of Rheumastop S, which adds various ingredients to Rheumastop® and provides more consumer choices.   The radio advertisement for Rheumastop® is planning to use “Stop Rheumastop” as a repeated melody to raise awareness by imprinting the image of the brand name in the minds of consumers. Six bumper ads (video ad of around 6 seconds each), which feature actor Jo Jae-yoon as a model, will be launched in YouTube and theaters. Mr. Jo appears as various characters, both male and female, in the video clips that parody famous films and TV drama series such as Peppermint Candy, One Fine Spring Day, and Taejo Wang Geon and delivers the message “Stopped once applied! Pain stops! Rheumastop®” with some laugh.   An official related to Rheumastop® in Samyang Biopharmaceuticals Corporation said, “Better brand awareness leads to greater market share in the over-the-counter drug market. In addition to the advertisements, we are going to raise awareness and reliability about the product and its company through a variety of promotional activities such as academic conferences.”  

  • Samyang Biopharm 2019.02.18
    Samyang Biopharm Participates in ”Arab Health 2019”
    Samyang Biopharm Participates in ”Arab Health 2019”

        Samyang Biopharmaceutical Corp. partook in "Arab Health", which is the largest medical exhibition and conferences in the Middle East, from January 28 to 31. At the exhibition, Samyang Biopharm showcased its products, including surgical sutures such as Trisorb, Neosorb, Monosorb, Monofast, anti-bacterial sutures, and wound management products such as SurgiGuard, ORC hemostasis   During the event, Samyang Biopharm enjoyed the opportunity to meet with new overseas customers and deepen the understanding of the global market trends in the industry.   Particularly, on the first day of the exhibition, Yun Kim, Chairman and CEO of Samyang Holdings Corp.- which is the holding company of Samyang Biopharm- paid a visit to Samyang Biopharm’s booth to encourage the employees and stressed the significance of developing global business opportunities through international exposure of the company.  

  • Samyang Biopharm 2018.12.19
    Samyang Biopharmaceuticals Corporation Releases Rheumastop S, an Arthritis Patch Medication
    Samyang Biopharmaceuticals Corporation Releases Rheumastop S, an Arthritis Patch Medication

    - Rheumastop® Plaster line upgrade with two types of Rheumastop S - Release of Rheumastop S Cool with cooling effects and Rheumastop Lavender for              a better scent. Rheumastop Hot with heating effects to be released soon - Continuous strengthening of patch marketing system since last year, “aiming to expand    the pharmaceutical market share and advertise the corporation”     Samyang Biopharmaceuticals Corporation is upgrading its arthritis patch medication line.   On December 19, Samyang Biopharmaceuticals Corporation announced that it is releasing Rheumastop S Plaster, a brand under the same family as the arthritis patch medication, Rheumastop® Plaster (contains Diclofenac).   Rheumastop S contains additional ingredients compared to the existing Rheumastop, providing further choice options to consumers. Two types of products were released: Rheumastop S Cool, which has a cooling effect thanks to the added menthol, and Rheumastop S Lavender, which features a lavender scent that blocks out the original scent of the medicinal product. Samyang Biopharmaceuticals Corporation is also planning on releasing Rheumastop S Hot in the first quarter of 2019 which will come with the heating effects of Vanillyl Butyl Ether.   Rheumastop is an arthritis patch medication developed by Samyang Biopharmaceuticals Corporation. This product is meant to be applied one patch a day on the affected area. The Diclofenac contained in the patch, an anti-inflammatory analgesic drug, will then penetrate locally through the skin and relieve pain in the infected area. Because this product is only applied on the affected area, it prevents any side effects on areas like the stomach and digestive tract that commonly occur with the edible version of the same ingredient. Since last year, Samyang Biopharmaceuticals Corporation has been strengthening its patch marketing system by directly selling its patch products and more. Last July, the corporation began to directly sell their Nicostop® patches, an initiative that was followed by the direct sales of Rheumastop in April this year. Nicostop® is the No. 1 nicotine patch on the market in terms of sales.

  • Samyang Biopharm 2018.12.10
    Samyang Biopharmaceuticals Corporation Receives 50 Million US Dollar Export Tower Award and Iron Tower Order of Industrial Service Merit...
    Samyang Biopharmaceuticals Corporation Receives 50 Million US Dollar Export Tower Award and Iron Tower Order of Industrial Service Merit Award

    - Exports anticancer drugs that contain Paclitaxel and pharmaceutical ingredients to Europe, Southeast Asia, Japan, South America and more - Exports biodegradable surgical suture threads and has the world’s largest market share in the surgical suture thread industry - Pursues open innovation at the Pangyo research center and the American branch, promising a competitive edge and faster development in terms of new biopharmaceutical products     On December 10, Samyang Biopharmaceuticals Corporation(CEO: Eom Tae-Ung) announced that the corporation received the USD 50 Million Export Tower Award and the Iron Tower Order of Industrial Service Merit Award at Korea’s 55th Trade Day Ceremony, hosted by the Korea International Trade Association at COEX in Seoul on the December 7, 2018.   Samyang Biopharmaceuticals Corp. developed anticancer drugs called Genexol® Inj. and Genexol® PM Inj., biodegradable surgical suture threads and others, exporting these products to approximately 40 countries and 140 clients in the United States, Europe, Japan, Southeast Asia, China, South America, Africa and more. Genexol® Inj. is a medication used for treating lung cancer, ovarian cancer, and breast cancer, while Genexol® PM Inj. is an anticancer drug that minimizes the side effects caused by Genexol® Inj. by using Samyang Biopharmaceuticals Corp.’ drug delivery technology.   In 1995, Samyang Biopharmaceuticals Corp. became the first in the world to mass produce Paclitaxel by using the plant cell cultivation technique. Currently, the corporation manufactures Paclitaxel and anticancer drugs in manufacturing facilities approved by European and Japanese GMP (Good Manufacturing Practices), exporting them to Europe, Southeast Asia, Japan, South America and more. Samyang Biopharmaceuticals Corp. is the only corporation in Korea to have cellulotoxic anticancer drug production facilities that has earned GMP from both Europe and Japan.   Genexol® Inj., the anticancer drug developed and produced by Samyang Biopharmaceuticals Corp. has over 50% of the market share, making the company the top seller amongst all drugs that contain Paclitaxel. This year, the corporation released four new drugs, beginning with Protezomib® Inj., a drug for multiple myeloma, and drugs for hematologic malignancy – Lenalid® Tab, Azalid, and Decilid. Based on its capacity differentiation strategy, Samyang Biopharmaceuticals Corp. focused on expanding its anticancer drug portfolio. The corporation plans to continue to expand its anticancer drugs pipelines with the goal of targeting the global market.   Biodegradable surgical suture threads are surgical threads that naturally dissolve in the human body after a certain period of time. Samyang Biopharmaceuticals Corp. was the first in Korea to succeed in developing biodegradable threads and began its commercial manufacturing in 1997. Currently, the corporation exports the biodegradable surgical suture threads to approximately 40 countries, including the United States, and Japan, as well as countries in Europe, Southeast Asia, Central and South America, and Africa. The corporation also has the world’s largest market share in the surgical suture thread industry.   Samyang Biopharmaceuticals Corp. is the second corporation in the world to have succeeded in the development of Oxidized Regenerated Cellulose (ORC) styptic, based on their accumulated expertise and knowledge built by developing and manufacturing biodegradable surgical suture threads. ORC styptics are styptics that are most often used during surgical operations to prevent bleeding in body parts that are undergoing surgery. In 2015, the corporation released the product in Korea, named SurgiGuard®, and is currently in the process of exporting it to the United States, China, Europe and more. Recently, the corporation has also been developing the biodegradable version, in preparation to enter the cosmetic surgery market.   CEO Eom Tae-Ung described that “Samyang Biopharmaceuticals Corp. is continually growing through the Open Innovation method of communicating with internal and external professionals,” adding that “the corporation seeks to develop new drugs in the anticancer and orphan drug industries, with the Pangyo Samyang Discovery Center and Samyang Biopharmaceuticals USA leading the projects, as well as in collaboration with other global corporations, and research centers.”   Since 2016, Samyang Biopharmaceuticals Corp. has grouped the marketing teams and research professionals together at the Pangyo Samyang Discovery Center. This was to achieve Open Innovation by encouraging further communication internally and externally. This August, Samyang Biopharmaceuticals USA was established in Boston, USA, the global center of the biopharmaceutical industry. This branch focuses on fostering networks with global corporations and research centers, in search for possible new biopharmaceutical drug ideas and materials to accelerate the speed in which the corporation can develop new drugs.   Samyang Biopharmaceuticals Corp. currently focuses its research and development, as well as business expansion, in three areas: △anticancer drugs using the Drug Delivery System, △new drugs that will lead the future of cancer treatment, and △medical devices that use high-tech biodegradable materials.  

  • Samyang Biopharm 2018.12.04
    Samyang Biopharmaceutical Corp. attends “4th Oncolytic Virotherapy Summit 2018”
    Samyang Biopharmaceutical Corp. attends “4th Oncolytic Virotherapy Summit 2018”

      Samyang Biopharmaceutical Corp. (abbrv. as “SYB” below) partook in the “4th Oncolytic Virotherapy Summit 2018”, a conference dedicated to improving the successful commercialization of oncolytic viruses, in stand-alone and combination therapies, which was held from Dec 04 - 06, 2018 at Hilton Boston Back Bay, Boston, Massachusetts, USA. At this networking site, SYB had the opportunity to meet the industry peers from many leading pharmaceutical companies such as Merck, Pfizer, Boehringer Ingelheim, Amgen, Sillagen, etc. and by learning from their case studies, gathered insights into research trends in oncolytic virotherapy including combination therapy.   SYB presented its research findings, which was a total of 5 topics, as followings: 「Clinical data presentations for oncolytic virotherapy combinations」, 「Discovery Considerations for Next Generation Oncolytic」,  「Viruses Discovery Considerations for Monotherapies and Combination Therapies」,  「Novel Effective Delivery Technologies」, and 「Improving Manufacturing to Minimize Time & Cost」.  

  • Samyang Biopharm 2018.11.28
    Samyang Biopharmaceuticals Corp. donates to the Indonesia Red Cross Society
    Samyang Biopharmaceuticals Corp. donates to the Indonesia Red Cross Society

    Samyang Biopharmaceuticals Corp., a dedicated partner of Kalbe Indonesia since 2003, decided to donate 30,000 US dollar to the Indonesia Red Cross Society after the tragic Earthquake and Tsunami that struck the Islands on Sept 2018.   Overseas Team manager Mr. SungSeup Shin and Senior manager Dr. Yongsoon Hwang from Samyang together with PR team from Kalbe, delivered the donation directly to the Red Cross Secretary Manager Dr. Ritola Tasmaya during their business trip to Indonesia.   Samyang Biopharmaceuticals Corp. who has a strong business partnership in South East Asia, expresses its deepest condolence and preys only for the fast recovery and the brightest future for our friends in Indonesia who had been struck with grief.  

  • Samyang Biopharm 2018.11.03
    Samyang Biopharmaceuticals Corp. attends ‘2018 AAPS PharmSci 360’ & ‘2018 SITC Annual Meeting’
    Samyang Biopharmaceuticals Corp. attends ‘2018 AAPS PharmSci 360’ & ‘2018 SITC Annual Meeting’

      Samyang Biopharmaceuticals Corp. attended 2 following Science conferences in Washington D.C. in USA: ‘2018 AAPS PharmSci 360’ on Nov. 3-8 and ‘2018 Society for Immuno-Therapy of Cancer Annual Meeting (SITC 2018)’ on Nov. 7-11.   Through These meetings, the researchers from Samyang Biopharmaceuticals Corp. enjoyed the fruitful opportunities to identify the latest research trends in the fields of pharmacology as well as immune-cancer therapy, networking with various researchers and exports in the industry.   Samyang Biopharmaceuticals Corp. presented 6 research topics include 「Pharmacokinetics study of sorafenib tablet (SYO-1644) with improved bioavailability in beagle dogs」, 「Solid Dispersion of Sorafenib Tosylate with Enhanced Solubility and Bioavailability」, 「Simultaneous Determination of Sunitinib and Its Active Metabolite N-desethyl Sunitinib in Rat/Beagle Dog Plasma Using LC/MS/MS」.

  • Samyang Biopharm 2018.10.12
    Samyang Biopharm Participates in CPhI Worldwide 2018
    Samyang Biopharm Participates in CPhI Worldwide 2018

      From October 9 to 11, Samyang Biopharm partook in the international pharmaceutical exhibition, CPhI Worldwide 2018, held in Madrid, Spain.   CPhI Worldwide is the world’s largest pharmaceutical exhibition with over 42,000 participants from as many as 155 countries around the world. It is held annually in the major cities of Europe.   Samyang Biopharm received the opportunity to expand upon the scope of exports by promoting Samyang products and technology, including anti-cancer drugs, patches, and DDS (Drug Delivery System), in addition to meetings with current partners from as many as 50 overseas pharmaceutical companies.  

  • Samyang Biopharm 2018.10.01
    Samyang Biopharmaceuticals Corporation Launches Dose-Differentiated 40mg Decirid Inj.
    Samyang Biopharmaceuticals Corporation Launches Dose-Differentiated 40mg Decirid Inj.

      Samyang Biopharm is solidifying a position in the blood cancer therapeutics market strategizing the differentiated dosage of anti-carcinogens.   Samyang Biopharm became the first to succeed in localizing myelodysplastic syndrome (MDS) medication, Decitabine, and has differentiated the dosage to release the Decirid Inj. 40mg (ingredient name: Decitabine) on October 1.   Samyang Biopharm’s Decirid is the only 40mg product among Decitabine medications both sold and manufactured in Korea. The Dacogen Inj. (Janssen Korea Ltd.) and Debikin Inj. (Boryung Pharmaceutical Co. Ltd.), currently sold in Korea, are all imported and sold in 50mg dosages. Although all products have thus been imported in order to maintain the stability of Decitabine, Samyang Biopharm has become the first to localize the medication at a specialized manufacturing facility utilizing in-house technology.   Samyang Biopharm’s strategy involves differentiating our Decirid dosage to 40mg in order to reduce the fiscal burden on patients while minimizing the waste of insurance finances. The main dosage of Decitabine is 20mg per square meter of the body surface area. For Koreans, about 30mg is generally used per dose.

First Page 1 2 3 4 5 Next Page Last Page
1 2 3 4 5
News Search